# CD4<sup>+</sup> and CD8<sup>+</sup> T cells have opposing roles in breast cancer progression and outcome

#### **Supplementary Material**



#### **Supplemental Figure 1**

(A) to (C) Dynamic changes of CD4<sup>+</sup> to CD8<sup>+</sup> T cell ratios in peripheral blood (A), spleen (B) and draining lymph nodes (C) at the different stages of tumor development in two models. Tumor- free BALB/c (4T1) and C57BL/6 (E0771) mice were included as controls. The treatment procedure was identical as that described in Figure 1. T cells were isolated from the organs and proportions of CD4<sup>+</sup> and

CD8<sup>+</sup> T cells detected at the indicated time points using flow cytometry analyses by gating CD3<sup>+</sup> population. Results shown in (A) to (C) are mean  $\pm$  SE from four individual mice in each time point. \* *p*< 0.05 and \*\* *p*< 0.01 between the indicated two groups determined by paired student's T-test.



### **Supplemental Figure 2**

Dynamic analyses of tumor-infiltrating CD4<sup>+</sup>T cell subsets in mouse breast cancer models.

(A) and (B) Proportions of CD4<sup>+</sup> T cell subsets in TILs were analyzed at the indicated time points using flow cytometry analyses by gating CD4<sup>+</sup> population. Representative FACS graphs from 4T1- bearing mice
(A) and E0771-bearing mice (B) are shown. The treatment procedure was identical as that described in

Figure 1. TILs were isolated and intracellular staining performed after stimulation with PMA and ionomycin for 5 hours. **(C)** Total cell numbers of CD4<sup>+</sup> T cell subsets were concluded. Data shown are mean  $\pm$  SE from four individual mice in each group.



## **Supplemental Figure 3**

Distributions of CD4<sup>+</sup> T cell subsets in blood and spleens in breast tumor-bearing mice.

(A) Peripheral blood from two mouse breast tumor models were collected and total white blood cell numbers counted. The mouse treatment procedure was identical as that described in Figure 1. (B) and (C) The dynamic distributions of CD4<sup>+</sup> T cell subsets in spleens from breast tumor-bearing mice in two models were analyzed at the indicated time points using flow cytometry analyses by gating CD4<sup>+</sup> population. The treatment procedure was identical as that described in Figure 1. T cells were isolated from the organs and intracellular staining performed after stimulation with PMA and ionomycin for 6 hours. Results shown in (A) to (C) are mean  $\pm$  SE from four individual mice in each time point. Tumor-free BALB/c (4T1) and C57BL/6 (E0771) mice were included as controls. \* *p*< 0.05 and \*\* *p*< 0.01 between the indicated two groups determined by paired student's T test.

#### Supplemental Table 1.

	Relapse-free Survival					
Variables	HR	95% CI	р	HR	95% CI	р
CD4 (>16)	3.92	1.48 to 10.36	0.005	2.61	1.17 to 5.82	0.02
CD8 (>13 )	0.06	0.01 to 0.47	6.71E-05	0.32	0.13 to 0.79	0.007
CD4/CD8 (>1.2)	10.87	2.46 to 47.23	5.01E-05	3.73	1.48 to 9.41	0.002
Stage ( III vs I + II)	11.94	4.31 to 33.07	1.53E-06	6.72	2.88 to 15.71	1.65E-05
Nodal (Positive)	16.71	3.76 to 74.26	1.35E-06	6.97	2.58 to 18.79	1.15E-05

A. Univariate analyses of factors associated with Relapse-free Survival and Overall Survival in breast cancer patients (n=81).

Note: Results obtained using the Cox proportional hazard regression model. Boldface indicates the significance of the *p* value.

# B. Mulvariate analyses of Hazard Ratios with Relapse-free Survival and Overall Survival in breast cancer patients (n=81).

	Relapse-free Survival			Overall survival		
Variables	HR	95% CI	р	HR	95% CI	р
CD4 (>16)	1.37	0.35 to 5.25	0.65	1.37	0.49 to 3.81	0.55
CD8 (>13 )	0.05	0.01 to 0.51	0.01	0.28	0.09 to 0.93	0.04
CD4/CD8 (>1.2)	0.65	0.08 to 5.48	0.68	0.69	0.17 to 2.78	0.60
Stage ( III vs I + II)	4.54	1.04 to 22.02	0.04	2.76	0.99 to 7.71	0.05
Nodal (Positive)	9.46	1.19 to 74.74	0.03	4.61	1.29 to 16.44	0.02

Note: Results obtained using the Cox proportional hazard regression model. Boldface indicates the significance of the *p* value.